MDR1 Antibodies

Santa Cruz Biotechnology offers a broad range of MDR1 monoclonal antibodies for studying multidrug resistance protein 1 (MDR1). MDR1 monoclonal antibodies are compatible with multiple research applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). MDR1, also known as P-glycoprotein, actively transports drugs and xenobiotics across cell membranes, significantly impacting the pharmacokinetics of numerous therapeutic agents. MDR1 expression patterns are frequently linked to drug resistance in cancer cells, making it a crucial focus in research aimed at addressing therapeutic challenges. Understanding MDR1 function and regulation is fundamental for developing new strategies to enhance drug efficacy and improve patient outcomes. Researchers worldwide are investigating MDR1's role in various physiological and pathological processes. Current studies focus on identifying novel approaches to modulate MDR1 activity for better treatment outcomes. Ongoing research continues to reveal new aspects of MDR1's involvement in cellular defense mechanisms and drug resistance. Santa Cruz Biotechnology monoclonal antibodies for MDR1 support researchers in advancing scientific knowledge and developing innovative solutions for drug resistance challenges.